Six additional lung cancer patients with KIF5B-RET (n = 3), CCDC6-RET (n = 2) or SDC4-ROS1 (n = 1) were also detected with activating mutations in NRAS, EGFR, and PIK3CA, as well as loss of function mutations in BRCA1 and PTEN. Moreover, two FGFR3-TACC3-positive cases also harbored KRAS-activating mutations. This evidence concerns the gene FGFR3 and lung cancer.